Nurix therapeutics to participate in upcoming investor conferences

San francisco, april 03, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that arthur t. sands, m.d, ph.d., president and chief executive officer of nurix, hans van houte, nurix's chief financial officer, and jason kantor, ph.d., nurix's chief business officer, will participate in the following conferences in april:
NRIX Ratings Summary
NRIX Quant Ranking